Key result
SCH6 selects for HCV resistance mutations A156T and R109K, with A156T reducing viral fitness.
Population
Hepatitis C virus RNA replicons (genotype 1b derived from two different strains)
Design
Preclinical
Authors
Loading...
May limit NS3/4A inhibitor durability in HCV; leaves open clinical translation and need for compensatory mutation studies.
The study identifies specific mutations (A156T/A156V and R109K) in HCV genotype 1b replicons that confer resistance to the NS3/4A protease inhibitor SCH6, with compensatory mutations restoring viral fitness.
Yi et al. (2005) studied Hepatitis C virus. SCH6 was evaluated on Resistance mutations in HCV RNA replicons. SCH6 treatment of hepatitis C virus replicons selected for resistance mutations A156T/A156V and R109K, with A156T conferring high-level resistance and reducing viral fitness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: